Editas brings on Sarepta CMO—for CEO swap, not the vacant CMO role Regeneron's bid for COVID-19 drug's full approval hits snag as FDA extends review Healthcare billionaires in 2022: From HCA's founder to a Doximity entrepreneur Following a $600M fundraising, robot maker CMR Surgical maps out European expansion Twist in Protagonist story as FDA seeks to rescind breakthrough nod 'based on observed malignancies' Merck evades 'aggressive marketing' claims tied to once-dominant Zostavax shot Hackensack Meridian, Englewood Health call off merger after legal and regulatory roadblocks AACR: By microdosing tumors, Takeda and Presage examine how to trigger the immune system to help fight cancer FDA urges creation of racial, ethnic recruitment plans for clinical trials Evelo hits the brakes on atopic dermatitis drug development after phase 1 failure Providence Health agrees to pay DOJ $22M to settle allegations over unnecessary surgeries Akron Bio debuts new plasmid DNA plant on quest to ease regenerative medicine bottlenecks Optum Health has raised its expectations for value-based care participation. Here's why Boston Scientific infuses €100M into Ireland facility for carbon-neutral manufacturing Featured Story | By Annalee Armstrong Editas is bringing on Sarepta’s Chief Medical Officer Gilmore O’Neill, M.B., but not to fill that empty role at the gene editing biotech. He will instead replace Chairman, President and CEO James Mullen, who is taking on the executive chairman role. read more |
| |
|---|
|
| | Full-time Consulting Careers IPM is an industry leader in Life Sciences consulting and has managed projects for more than 150 biotech, pharma, and medtech companies. Learn how you can lead a variety of impactful projects with us. Explore here! |
Top Stories By Angus Liu Just as Regeneron’s COVID-19 antibody combination, REGEN-COV, is sidelined in the U.S. thanks to omicron, the drug has hit a hiccup on its quest for a full FDA nod. read more By Heather Landi More than 200 healthcare executives, 217 to be exact, are now in the “three comma club,” as Forbes calls it, and are among the 2,668 billionaires on Forbes’ 2022 list. There are 32 American business leaders on Forbes' list who made their fortunes in healthcare. Meet 20 of this year's healthcare billionaires. read more By Andrea Park What’s next for a surgical robotics developer that’s been riding high after raising a monstrous £425 million last summer? According to CMR Surgical, world domination—or, at the very least, European domination. read more By Nick Paul Taylor The FDA gave Protagonist Therapeutics’ rusfertide breakthrough designation last year. Now, the agency wants to take it back “based on observed malignancies,” triggering a 30% drop in Protagonist’s stock as investors scrambled to figure out the implications of the news. read more By Fraiser Kansteiner Early this week, a U.S. District Judge granted Merck's bid to toss claims it waged a “false and misleading” marketing campaign for Zostavax, which hasn’t been sold in the U.S. since Nov. 2020. The dismissal hinged in part on a technicality. read more By Heather Landi Hackensack Meridian Health and Englewood Health have given up their fight against the Federal Trade Commission and dropped their plans for a merger. read more By Conor Hale By using a device that shows how tiny amounts of drugs perform inside the body, Takeda is examining two therapies that could help break down the barriers protecting solid tumors from the body's immune system. read more By Gabrielle Masson The FDA is prioritizing diversity among clinical trial participants in the U.S., with new draft guidance aimed at boosting enrollment of participants from underrepresented racial and ethnic populations. read more By James Waldron Inflammatory-disease-focused Evelo Biosciences has hit the brakes on one of its atopic dermatitis treatments after a phase 1 trial failed to demonstrate clinical benefit. read more By Robert King Providence Health agreed to pay the Justice Department $22 million to settle allegations of unnecessary surgical procedures being conducted at one of its hospitals. read more By Fraiser Kansteiner As cell and gene therapies, mRNA vaccines and other cutting-edge meds come into their own, developers have put a strain on the industry’s manufacturing capacity. That’s where biopharma building block outfits like Akron Bio come in. read more By Paige Minemyer UnitedHealth Group posted its first-quarter earnings on Thursday morning, where it reported $5 billion in profit. read more By Andrea Park Boston Scientific is banking on the luck of the Irish to help expand its sustainable manufacturing efforts. read more |
